

HONGBO YANG

Vice President

Phone: 617 425 8175

Fax: 617 425 8001

hongbo.yang@analysisgroup.com

111 Huntington Avenue

14th Floor

Boston, MA 02199

Dr. Yang specializes in health economics and outcomes research. She has extensive experience in evaluating the clinical and economic impacts of a broad range of diseases and treatments. She has conducted and directed numerous studies in a variety of therapeutic areas, including autoimmune diseases, infectious diseases, diabetes, blood disorders, oncology, women's health, and central nervous system diseases. Her recent work includes cost-effectiveness analysis, budget impact analysis, systematic literature review, and evaluation of treatment efficacy, health care resource use, direct costs, indirect costs, and patient-reported outcomes. She has led the submission of economic models to multiple health technology assessment agencies (HTAs), including NICE, CADTH, INESSS, and OHTAC. Dr. Yang's work has been published in many peer-reviewed journals and has been featured at various conferences.

Education

Ph.D., biology, University of Illinois, Urbana-Champaign

M.S., statistics, University of Illinois, Urbana-Champaign

B.S., biochemistry, Nankai University, Tianjin, China

Professional Experience

2017-Present	Vice President, Analysis Group
2013-2016	Manager, Analysis Group
2011-2012	Associate, Analysis Group
2009-2010	Senior Analyst, Analysis Group

PUBLICATIONS in PEER-REVIEWED JOURNALS

- Ostrosky-Zeichner L, Harrington R, Azie N, **Yang H**, Li N, Zhao J, Koo V, Wu EQ. A Risk Score for Fluconazole Failure among Patients with Candidemia. *Antimicrob Agents Chemother*. 2017 Mar 6. [Epub ahead of print]
- Harrington R, Lee E, **Yang H**, Wei J, Messali A, Azie N, Wu EQ, Spalding J. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis. *Adv Ther*. 2017 Jan;34(1):207-220.
- Kontoyiannis DP, **Yang H**, Song J, Kelkar SS, Yang X, Azie N, Harrington R, Fan A, Lee E, Spalding JR. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. *BMC Infect Dis*. 2016 Dec 1;16(1):730.
- Massoudi M, Balk M, **Yang H**, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S. Number needed to treat and associated incremental costs of treatment with

enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. *J Med Econ*. 2017 Feb;20(2):121-128.

- Andes D, Azie N, **Yang H**, Harrington R, Kelley C, Tan RD, Wu EQ, Franks B, Kristy R, Lee E, Khandelwal N, Spalding J. Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients. *Antimicrob Agents Chemother*. 2016 May 23;60(6):3398-406
- Soliman AM, **Yang H**, Du EX, Kelley C, Winkel C. The direct and indirect costs associated with endometriosis: a systematic literature review. *Hum Reprod*. 2016 Apr;31(4):712-22.
- Setyawan J, **Yang H**, Cheng D, Cai X, Signorovitch JE, Xie J, Erder MH. Developing a risk score to guide individualized treatment selection in attention/deficit hyperactivity disorder. *Value Health*. 2015 Sep;18(6):824-31.
- Bonthapally V, **Yang H**, Ayyagari R, Tan RD, Cai S, Wu E, Gautam A, Chi A, Huebner D. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post ASCT: median overall survival meta-Analysis. *Curr Med Res Opin*. 2015 Jul;31(7):1377-89
- Bonthapally V, Wu E, Macalalad A, **Yang H**, Shonukan O, Liu Y, Chi A, Huebner D. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data. *Curr Med Res Opin*. 2015 May;31(5):993-1001.
- Soliman AM, **Yang H**, Du EX, Kelkar SS, Winkel C. The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013. *Am J Obstet Gynecol*. 2015 Aug;213(2):141-60.
- Macalalad AR, McAuliffe M, **Yang H**, Kageleiry A, Zhong Y, Wu EQ, Shonukan O, Bonthapally V. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. *Curr Med Res Opin*. 2015 Mar;31(3):537-45
- Fuldeore M, **Yang H**, Du EX, Soliman AM, Wu EQ, Winkel C. Healthcare utilization and costs in women diagnosed with endometriosis pre- and post-diagnosis: a longitudinal analysis of claims databases. *Fertil Steril*. 2015 Jan;103(1):163-71.
- Lachaine J, De G, Sikirica V, van Stralen J, Hodgkins P, **Yang H**, Heroux J, Ben Amor L. Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in Quebec. *Can J Psychiatry*. 2014 Nov;59(11):597-608
- Campone M, **Yang H**, Faust E, Kageleiry A, Signorovitch JE, Zhang J, Gao H. Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe. *J Med Econ*. 2014 Aug 28:1-20.
- **Yang H**, Chaudhari P, Zhou ZY, Wu EQ, Patel C, Horn DL. Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States. *Appl Health Econ Health Policy*. 2014 Feb;12(1):85-93
- Wong MK, **Yang H**, Signorovitch JE, Wang X, Liu Z, Liu NS, Qi CZ, George DJ. Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. *Curr Med Res Opin*. 2014 Apr;30(4):537-45.
- Sikirica V, Xie J, He TL, Erder M, Hodgkins P, **Yang H**, Samuelson T, and Wu EQ. Immediate-release versus extended-release guanfacine for treatment of attention-deficit/hyperactivity disorder. *Am J Pharm Benefits*. 2013;5(4):e85-e94
- Xie J, Diener M, De G, **Yang H**, Wu EQ, Namjoshi M. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-)

advanced breast cancer in the United States. *J Med Econ*. 2013;16(2):278-88.

- Erder MH, Signorovitch JE, Setyawan J, **Yang H**, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ. Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity. *J Med Econ*. 2012;15(6):1078-87.
- Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, **Yang H**, Goldblum O, Okun MM, Mulani PM. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial. *Br J Dermatol*. 2012 Dec;167(6):1374-81.
- Bron M, Marynchenko M, **Yang H**, Yu AP, Wu EQ. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. *Postgraduate Medicine*, Jan 2012;124(1), 124-132.
- Kim Le T, Winfree KB, **Yang H**, Marynchenko M, Yu AP, Frois C, Wu EQ. Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients. *J Med Econ*. 2012;15(4):786-95
- Yu AP, **Yang H**, Wu EQ, Setyawan J, Mocarski M, Blum S. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. *J Med Econ* 2011, 14(3):315-323.
- **Yang H**, Yu AP, Wu EQ, Yim YM, Yu E. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer. *J Med Econ* 2011, 14(5):542-552.
- Hines KA, Cryderman DE, Flannery KM, **Yang H**, Vitalini MW, Hazelrigg T, Mizzen CA, Wallrath LL. Domains of heterochromatin protein 1 required for *Drosophila melanogaster* heterochromatin spreading. *Genetics* 2009, 182(4):967-977.
- **Yang H**, Mizzen CA. The multiple facets of histone H4-lysine 20 methylation. Review. *Biochem Cell Biol* 2009, 87(1):151-161.
- **Yang H**, Pesavento JJ, Starnes TW, Cryderman DE, Wallrath LL, Kelleher NL, Mizzen CA. Preferential dimethylation of histone H4-lysine 20 by Suv4-20. *J Biol Chem*. 2008 May 2;283(18):12085-92.
- Pesavento JJ, **Yang H**, Kelleher NL, Mizzen CA. Certain and progressive methylation of histone H4 at lysine 20 during the cell cycle. *Mol Cell Biol* 2008, 28(1):468-486.
- Shi J, Li J, **Yang H**, Wang K, Wu Q, Zhang J. Proliferation and apoptosis of smooth muscle cells in benign prostate hyperplasia. *Chinese J. Pathophysiol* 2005, 21: 817-819.
- **Yang H**, Elcock AH. Association lifetimes of hydrophobic amino acid pairs measured directly from molecular dynamics simulations. *J Am Chem Soc* 2003, 125(46):13968-13969.